The center will be housed in Michelson Hall, a state-of-the-art research facility. The aim of the center is to establish a convergence of researchers across science and engineering to work together on multidisciplinary approaches for the development of improved health care through new drugs, diagnostics, and medical devices.
The Agilent CoE will provide a collaborative scientific environment with access to new Agilent instrumentation and technologies for undergraduate and graduate students, local customers, and offer broad exposure to researchers who are leaders in their respective fields.
Key to the Agilent CoE will be a collaboration with principal investigator Dr. Valery Fokin, whose research focuses on chemical reactivity and biological interactions at the molecular level.
The Fokin lab will contribute to multiple collaborative drug discovery projects ranging from chemical synthesis of screening and focused libraries and biological assay implementation to the development of targeted drug delivery systems, diagnostics, and vaccines.
Agilent partners with pharmaceutical companies to develop immunohistochemical-based diagnostics for cancer therapy. The company provides instruments, software, services, and solutions to the life sciences, diagnostics and applied chemical markets. It generated revenues of USD4.20 bn in fiscal 2016 and employs about 13,000 people worldwide.
The USC Michelson Center for Convergent Bioscience brings together a diverse network of premier scientists and engineers from the USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering, and Keck School of Medicine of USC to solve intractable problems from cancer, to neurological disease, to cardiovascular disease.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine